Related Experiment Video
Updated: Oct 2, 2025
09:01
Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
Published on: September 27, 2013
11.3K
Combined Therapeutics for Atherosclerosis Treatment Using Polymeric Nanovectors
Baltazar Hiram Leal1, Brenda Velasco1,2, Adriana Cambón1,2
1Colloids and Polymers Physics Group, Department of Particle Physics, Faculty of Physics and Health Research Institute, Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Pharmaceutics
|February 26, 2022
Summary
This study developed targeted nanoparticles that deliver both atorvastatin and miRNA-124a to treat atherosclerosis. This combination therapy effectively reduced inflammation and LDL accumulation in cells, showing promise for cardiovascular disease treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Cardiovascular Research
Background:
- Atherosclerosis, a major risk factor for cardiovascular diseases (CVDs), necessitates advanced therapeutic strategies.
- Current statin therapies have limitations; combining drugs with microRNAs (miRNAs) in nanocarriers offers synergistic effects and improved outcomes.
- Targeted delivery to inflamed endothelium is crucial for effective atherosclerosis treatment.
Purpose of the Study:
- To develop and characterize novel polymeric nanoparticles (PLGA NPs) for co-delivery of atorvastatin (ATOR) and miRNA-124a.
- To functionalize NPs with an antibody targeting vascular adhesion molecule-1 (VCAM1) for specific delivery to inflamed arterial endothelium.
- To evaluate the therapeutic efficacy of dual-loaded NPs in reducing atherosclerosis markers.
Main Methods:
- Synthesis and characterization of PLGA nanoparticles encapsulating ATOR and miRNA-124a.
- Functionalization of NPs with anti-VCAM1 antibodies for targeted cell binding.
- In vitro assessment of NP cytotoxicity, cellular uptake, cargo release, and anti-inflammatory effects in activated macrophages and endothelial cells.
- Evaluation of NP impact on low-density lipoprotein (LDL) accumulation and cellular morphology.
Main Results:
- Developed non-toxic, VCAM1-targeting NPs capable of sustained cargo release.
- Dual-loaded NPs significantly reduced pro-inflammatory cytokines (IL-6, TNF-α) and reactive oxygen species (ROS).
- ATOR and miRNA-124a co-delivery via NPs markedly inhibited LDL accumulation and detrimental cellular morphology changes.
Conclusions:
- The developed VCAM1-targeted nanoparticles are effective delivery vectors for combination therapy against atherosclerosis.
- Simultaneous delivery of atorvastatin and miRNA-124a demonstrates synergistic therapeutic potential, outperforming single-drug approaches.
- This nanomedicine approach offers a promising strategy for managing atherosclerosis and related cardiovascular diseases.
More Related Videos
Related Concept Videos
01:26Atherosclerosis III: Management
56
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
56
01:27Peripheral Artery Disease III: Interprofessional Care
44
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
44
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
267
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
267
01:27Coronary Artery Disease V: Interprofessional Care
53
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
53
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
236
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
236
01:23Atherosclerosis IV: Nursing Management
93
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
93